• ES - español
  • EN - English
Parliamentary question - E-002264/2021Parliamentary question
E-002264/2021

    State of the Commission’s negotiations with Novavax, Valneva and other COVID-19 vaccine manufacturers

    Question for written answer  E-002264/2021
    to the Commission
    Rule 138
    Nicolás González Casares (S&D)

    A few months ago, the Commission announced that it was in talks to conclude early purchase agreements with Novavax and Valneva, two COVID-19 vaccine manufacturers. I would like to know when the Commission will announce what agreement was reached concerning these contracts and, more importantly, if this time – contrary to what happened previously with other vaccine manufacturers – the Commission will make these contracts fully public.

    Moreover, I would welcome an update on any exploratory talks with other promising vaccine developers, such as the vaccine designed by the Spanish National Council for Scientific Research (CSIC), which will be administered as a single intranasal dose and will probably prevent transmission of the virus.

    Last updated: 17 May 2021
    Legal notice - Privacy policy